IL1B and systemic inflammatory response syndrome: β-glucan has been used in rat models and in vitro studies involving sepsis and SIRS, with good results once they convert the pro-inflammatory response to an anti-inflammatory response via the IL-1 antagonist receptor (IL-1 RA).